The ADP recently published a Pipeline analysis of new products for malaria, tuberculosis and neglected diseases as a working paper. It describes a comprehensive survey of new medicines, diagnostics and vaccines for malaria, TB and selected NTDs, which are currently in the pipeline for market entry by 2020. The paper also addresses potential challenges and key health system requirements for effective introduction of these products in low- and middle-income countries (LMICs). In support of evidence-based decision making, it is hoped that the paper can serve as a valuable resource for policy-makers, disease programme managers and other stakeholders involved in health programme planning. Read more |